86 papers found
Refreshing results…
Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas
Lymfoomahoitojen jälkeiset pitkäaikaishaitat, niiden ehkäisy ja seuranta
Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma
Incidence of solid cancer in patients with follicular lymphoma
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era
Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma
Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP
Treatment of diffuse large B‐cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP‐16)
Risk of Secondary Hematological Malignancies in Patients with Follicular Lymphoma: A Retrospective Analysis of 1045 Patients Treated in the Rituximab Era
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
Cardiovascular effects of mannitol infusion: a comparison study performed on mouse and human
Case Report: Chemotherapy in Conjunction With Blood–Brain Barrier Disruption for a Patient With Germ Cell Tumor With Multiple Brain Metastases
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma
Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients
Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma
Real-time monitoring of human blood-brain barrier disruption
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL)
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) ; prolonged remissions without survival plateau
Missing publications? Read more about our data sources.